Drugs / SIBP04
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04135898 | Oct 2019 → Mar 2020 | — | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05318443 | Apr 2020 → Dec 2022 | non-small cell lung carcinoma | Shanghai Institute Of Biological Products | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | China National Biotec Group Company Limited | Regulatory 第二款来了！生唯宁®获批上市 cnbg.com.cn ↗
1月8日，国药集团中国生物上海生物制品研究所研发的贝伐珠单抗注射液（商品名：生唯宁®）收到国家药品监督管理局（NMPA）核准签发的《药品注册证书》，这是中国生物第二款人源化单抗产品获批上市。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | China National Biotec Group Company Limited | 第二款来了！生唯宁®获批上市 cnbg.com.cn ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIBP-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135898 ↗ |
| Action | Inhibit | “Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04)” NCT05318443 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04)” NCT05318443 ↗ |
| Route | Other | “infusion in 90 minutes” NCT04135898 ↗ |